Art. -Nr.: HY-147337

MeTC7

5 Cited Publications

Kundenbewertung

Based on 5 publication(s) in Google Scholar

MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC₅₀ value of 2.9 μM. MeTC7 shows good antitumor effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.50%
CAS. Nr.: 1817841-22-7
Formel: C₃₂H₄₈BrN₃O₄
Molecular Weight:618.65

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

MeTC7 Chemical Structure

CAS. Nr.: 1817841-22-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC₅₀ value of 2.9 μM. MeTC7 shows good antitumor effects^[1].

IC₅₀ & Target

IC50: 2.9 μM (VDR)^[1].

In Vitro

MeTC7 (compound 5) shows potent VDR inhibition activity with an IC₅₀ value of 2.9 μM^[1].
MeTC7 disrupts the VDR-Ligand-binding domain in Silico^[1].
MeTC7 (250 nM; 18 h) suppresses RXRα and Importin-4 expressions in the ovarian cancer cell-line^[1].
MeTC7 (250 nM; 18 h) inhibits the viability of ovarian cancer cells and induces PARP1 cleavage^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

2008 cells
Concentration:

250 nM
Incubation Time:

18, 12 h
Result:

Reduced the expression of RXR-α, Importin-4 and increased cleaved PARP1 expression in 2008 cells.

Cell Viability Assay^[1]

Cell Line:

SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines
Concentration:

0, 0.25, 0.5, 0.75, 1.0, 1.25 μM
Incubation Time:

24 h
Result:

Reduced the viability of SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines.

In Vivo

MeTC7 (compound 5) (i.p.; 10 mg/kg) reduces the growth of the spontaneous transgenic TH-MYCN neuroblastoma and xenografts in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mice^[1]
Dosage:

10 mg/kg
Administration:

IP
Result:

Reduced the growth of xenografts derived from ovarian cancer, medulloblastoma, and pancreatic cancer cells.
Inhibited the growth of neuroblastoma cells and Xenografts.
Reduced MYCN expression and blocked the growth of TH-MYCN transgene-driven spontaneous neuroblastoma.

Chemical Information

CAS. Nr. 1817841-22-7
Appearance Solid
Molecular Weight 618.65
Formel C₃₂H₄₈BrN₃O₄
Color White to off-white
SMILES

O=C1N2C34[C@@](CC[C@]5([C@@]4([H])CC[C@]5([H])[C@H](C)CCCC(C)C)C)([H])[C@@]6(C(C=C3)(C[C@H](CC6)OC(CBr)=O)N2C(N1C)=O)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (5)

All In Vivo Efficacy StudyWBCell Imaging/Staining

Sort by:

Journal Impact Factor

Adv Mater

Reengineering Endogenous Targeting Lipid Nanoparticles (ENDO) for Systemic Delivery of mRNA to Pancreas. [Abstract]

2025 Oct;37(40):e2507657. PMID: 40504743

MeTC7 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Oct;37(40):e2507657. [Abstract]

Schematic representation of VDR blockade using MeTC7. Mice were administered 50 mg/kg of MeTC7 intraperitoneally, and 12 h later, mRNA LNPs were administered intravenously.

MeTC7 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Oct;37(40):e2507657. [Abstract]

To investigate the role of VDR, mice were pre-administering with VDR antagonist MeTC7 or PBS (control) 12 h before LNP administration. Representative IVIS images at 24 h post-injection of LNPs (0.5 mg/kg) in C57BL/6 mice (n = 4 biologically independent mice). Organs are arranged left to right as: heart, lung, spleen, pancreas, liver, kidneys and intestines.
Phytother Res

Betulinic Acid Enema Alleviates Colitis by Targeting Vitamin D Receptor to Protect the Intestinal Mucosal Barrier and Modulate Mucosa-Associated Microbiota. [Abstract]

2026 Jun 18. PMID: 42316556
Eur J Pharmacol

Calcitriol deficiency reduces myocardial ATP production with disturbed mitochondrial dynamics and increased uncoupling protein 2 expression. [Abstract]

2025 Sep 5:1002:177858. PMID: 40553779
Int J Mol Sci

DKS26 Alleviates Ischemia-Reperfusion Injury-Induced Acute Kidney Injury by Stabilizing Vitamin D Receptors to Inhibit the Inflammatory Pathway of NF-κB P65. [Abstract]

2025 Mar 25;26(7):2985. PMID: 40243616

MeTC7 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Mar 25;26(7):2985. [Abstract]

Western blot detection of p-P65^Ser311, P65, TNFα, MCP-1, KIM1, and NGAL expression in cells after administration of MeTC7 and/or DKS26-treated mRETCs; n = 3. MeTC7: 200 nM, DKS26: 100 μg/mL.

MeTC7 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Mar 25;26(7):2985. [Abstract]

Effects of MeTC7 and DKS26 on the nuclear translocation of p-P65Ser311 (red) observed by laser confocal microscopy.

MeTC7 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Mar 25;26(7):2985. [Abstract]

Western blot analysis of p-IKKβ, IKKβ, p-IKBα, and IKBα expression in cells treated with DKS26 and/or MeTC7; n = 3. MeTC7: 200 nM, DKS26: 100 μg/mL.
Biochem Biophys Rep

Exercise-induced vitamin D receptor and androgen receptor mediate inhibition of IL-6 and STAT3 in muscle. [Abstract]

2023 Dec 21:37:101621. PMID: 38205185

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 16.67 mg/mL (26.95 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6164 mL

8.0821 mL

16.1642 mL

5 mM

0.3233 mL

1.6164 mL

3.2328 mL

10 mM

0.1616 mL

0.8082 mL

1.6164 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (2.70 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Negar Khazan, et al. Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors In Vivo. J Med Chem [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6164 mL	8.0821 mL	16.1642 mL	40.4106 mL
	5 mM	0.3233 mL	1.6164 mL	3.2328 mL	8.0821 mL
	10 mM	0.1616 mL	0.8082 mL	1.6164 mL	4.0411 mL
	15 mM	0.1078 mL	0.5388 mL	1.0776 mL	2.6940 mL
	20 mM	0.0808 mL	0.4041 mL	0.8082 mL	2.0205 mL
	25 mM	0.0647 mL	0.3233 mL	0.6466 mL	1.6164 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MeTC7

Anti-Cancer Compound Library

Transcription Factor-Targeted Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) MeTC7

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MeTC7

Anti-Cancer Compound Library

Transcription Factor-Targeted Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) MeTC7

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MeTC7 Related Classifications

HY-147337 Related Classifications